Authors
Latest:
Intermittent Androgen Deprivation With the GnRH Antagonist Degarelix in Men With Biochemical Relapse of Prostate CancerIntermittent degarelix administered as described is noninferior to continuous androgen deprivation in maintaining PSA suppression, which indicates that degarelix is a suitable treatment option in men being considered for intermittent androgen ablation.
Latest:
Chemotherapy is Indicated, Yet Used Infrequently, in Patients With MIBCA review by André P. Fay, MD, on the data supporting the standard use of neoadjuvant and adjuvant chemotherapy for patients with muscle invasive bladder cancers.
Latest:
Dr Goy on Real-World Outcomes With CAR T-Cell Therapy in MCLAndre Goy, MD, discusses the implementation of CAR T-cell therapy in patients with relapsed/refractory mantle cell lymphoma.
Latest:
Dr Goy on Updated Data From ZUMA-2 With Brexu-Cel in MCLAndre Goy, MD, discusses updated data from the phase 2 ZUMA-2 trial, highlighting the expanded-access ZUMA-18 study in MCL.
Latest:
Dr. Goy on Durable Responses With Brexu-cel in the ZUMA-2 Trial in MCLAndre H. Goy, MD, discusses key findings from an assessment of durable responses in the phase 2 ZUMA-2 trial in relapsed/refractory mantle cell lymphoma.
Latest:
Dr. Goy on the Potential Utility of BTK Inhibitors as Maintenance in MCLAndre H. Goy, MD, discusses the potential utility of BTK inhibitors as maintenance therapy in mantle cell lymphoma.
Latest:
Dr Apolo on Adjuvant Pembrolizumab in Muscle-Invasive Urothelial CarcinomaAndrea B. Apolo, MD, discusses the AMBASSADOR Alliance A031501 trial of adjuvant pembrolizumab in locally advanced/muscle-invasive urothelial carcinoma.
Latest:
Novel Therapy in Urothelial Carcinoma: An Evolving Treatment LandscapeClosing out their discussion on urothelial carcinoma, key opinion leaders share clinical pearls and excitement for the evolving treatment landscape.
Latest:
Advice for Providers Treating Metastatic Colorectal CancerExperts provide advice for providers treating patients with metastatic colorectal cancer and highlight exciting potential combination treatments on the horizon.
Latest:
Dr. De Censi on the Hope for Biosimilars in the United StatesAndrea De Censi, MD, director of the medical oncology unit at the National Hospital E.O. Ospedali Galliera–SC Oncologia Medica in Genoa, Italy, discusses the hope for biosimilars in the United States.
Latest:
Dr Necchi on the Efficacy of TAR-200 Monotherapy in BCG-Unresponsive NMIBCAndrea Necchi, MD, discusses results from the phase 2b SunRISe-1 trial of TAR-200 in patients with Bacillus Calmette-Guérin (BCG)–unresponsive, high-risk, non–muscle-invasive bladder cancer.
Latest:
Adding CAR T-Cell Therapy to the Electronic Medical RecordAndrea Price, APN, discusses adding CAR T-cell therapy to the electronic medical record.
Latest:
The Applications of a Mixed Reality LaboratoryAndrea Sboner, MS, PhD, assistant professor of computational genomics in computational biomedicine and of pathology and laboratory medicine, Weill Cornell Medicine, discusses the applications of a mixed reality laboratory.
Latest:
Dr. Barrio on Neoadjuvant Chemo to De-Escalate Axillary Node Dissection in Breast CancerAndrea V. Barrio, MD, FACS, discusses how the use of neoadjuvant chemotherapy can help de-escalate axillary node dissection in select patients with breast cancer. Dissection can be a morbid procedure with longterm risks of lymphoma, impacting the quality of life for many patients.
Latest:
Dr. Wang-Gillam on Next Steps With Defactinib Combo in Pancreatic Ductal AdenocarcinomaAndrea Wang-Gillam, MD, PhD, discusses potential next steps with a novel combination regimen in pancreatic ductal adenocarcinoma.
Latest:
Dr. du Bois on Pazopanib in Advanced Ovarian CancerAndreas du Bois, MD, from Kliniken Essen Mitte in Essen, Germany, discusses a phase III trial exploring the effectiveness of treatment with maintenance pazopanib for patients with advanced ovarian cancer.
Latest:
Dr. du Bois on the Potential Impact of Cytoreductive Surgery in Ovarian CancerAndreas du Bois, MD, PhD, a professor of gynecologic oncology at Kliniken Essen Mitte, discusses the potential impact of cytoreductive surgery in ovarian cancer.
Latest:
Dr. Hochhaus on TFS With Nilotinib in Patients With CMLAndreas Hochhaus, MD, professor of Internal Medicine, Hematology and Oncology, interim head of the Department of Hematology and Medical Oncology, University Medical Center Jena in Germany, discusses results of the phase II ENESTFreedom study, which examined treatment-free survival (TFS) in patients with chronic myeloid leukemia (CML) who received frontline nilotinib (Tasigna).
Latest:
Dr. Kaubisch on the REACH Trials in HCCAndreas Kaubisch, MD, discusses the phase III REACH and REACH-2 trials in advanced hepatocellular carcinoma.
Latest:
Dr. Poveda on the Results of the SOLO2 Trial in Ovarian CancerAndres Poveda, MD, discusses the results of the phase 3 SOLO2 trial in advanced ovarian cancer.
Latest:
Emerging CD123-Targeted Therapies for BPDCN: Pivotal Trial Insights and Future PotentialDr. Andrew Lane discusses CD123-targeted therapies, particularly the antibody-drug conjugate pivekimab sunirine (PVEK), for treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). He notes PVEK's promising response rates and safety profile from early trial data, including lower risk of concerning side effects like capillary leak syndrome that can occur with the currently approved CD123-targeting agent tagraxofusp. In closing, he emphasizes accurately diagnosing BPDCN via expert hematopathology review and referral to specialized centers taking a cross-disciplinary approach, as combining emerging CD123-directed therapies with stem cell transplant as appropriate gives the best chance for optimal BPDCN management.
